Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-4191834. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 7/20 | 0.81 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-4191834 SCHEMBL29369341 | 1.00 | ALOX5 (0.81) | ALOX5PIK3CDCD274JAK1JAK3 | |
| SCHEMBL15803498 | 0.92 | ALOX5 (0.68) | ALOX5PIK3CDCD274JAK1JAK3 | |
| SCHEMBL3663603 | 0.89 | ALOX5 (0.64) | ALOX5PIK3CDHRH3 | |
| SCHEMBL333095 | 0.89 | ALOX5 (0.63) | ALOX5PIK3CDABL1HRH3 | |
| SCHEMBL332437 | 0.89 | ALOX5 (0.63) | ALOX5PIK3CDJAK1JAK3HRH3 | |
| SCHEMBL332628 | 0.88 | ALOX5 (0.63) | ALOX5PIK3CDCD274ABL1P2RX7 | |
| SCHEMBL332822 | 0.88 | ALOX5 (0.63) | ALOX5PIK3CDCD274JAK1JAK3 | |
| SCHEMBL332613 | 0.88 | ALOX5 (0.62) | ALOX5PIK3CDHRH3P2RX7CYP11B2 | |
| SCHEMBL332709 | 0.88 | ALOX5 (0.62) | ALOX5PIK3CD | |
| SCHEMBL332424 | 0.88 | ALOX5 (0.62) | ALOX5PIK3CDHRH3AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | claimed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | claimed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | claimed |
| US-20140171445-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2563359-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | Allergan, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2013019926-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-02-07 | — | — | WO | disclosed |
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110269807-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | ALLERGAN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269807-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | ALLERGAN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011137363-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | ALLERGAN, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011137363-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | ALLERGAN, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-7772269-B2 | Pyrazole analogs | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| EP-2097407-A1 | PYRAZOLE ANALOGS | Pfizer Products Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008065493-A1 | PYRAZOLE ANALOGS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008065493-A1 | PYRAZOLE ANALOGS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080125474-A1 | Pyrazole Analogs | PFIZER INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125474-A1 | Pyrazole Analogs | PFIZER INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125474-A1 | Pyrazole Analogs | PFIZER INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269807-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | ALOX15B, ALOX5, ALOX15 | ALOX5 2/4885PIK3CD 1694/4885CD274 2259/4885 |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | ALOX5 1/4885PIK3CD 1305/4885CD274 2601/4885 |
| US-20080125474-A1 | Pyrazole Analogs | IL33, CFTR, HRH1 | ALOX5 949/4885PIK3CD 2355/4885CD274 4041/4885 |
| US-20140171445-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | ALOX5, ALOX15, ALOX15B | ALOX5 1/4885PIK3CD 1354/4885CD274 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.